Mark Doucet has joined Valens GroWorks Corp. (CSE:VGW) as its president.
Mark Doucet has more than 25 years of senior executive experience. He has been involved in and advised on capital markets, infrastructure, commercial real estate, precious metals and other industries both foreign and domestic. Past service includes: President of a US junior exploration company, President of a business/government relations company, Founder and President of a wireless application company, and Vice President for several Canadian junior exploration companies, an international government/business consulting firm and an Atlantic Canada restaurant franchise. Mark served as Financial Officer and Development Planner for the privatization and redevelopment of Toronto’s Pearson International Airport. Mark and his wife have two boys, and reside in Ottawa.
Mark commented “Valens GroWorks Corp. has vastly superior products and people completely motivated to realize their vision of excellence by leading this quickly evolving industry. Drawing on this vision, I am passionately energized to help the Valens GroWorks team become an industry leader in this space.”
Robert van Santen, the Company’s CEO and Chair commented “I am particularly pleased that a seasoned and visionary leader like Mark has chosen our Company and its team as his vehicle to enter into this rapid-growth sector as the repeal of prohibition looms in Canada. The industry is in transition from the legacy world of commercial marijuana — legal, quasi-legal, gray market, illicit — to the future, which will see a fully institutionalized market.”
Read the full company profile.
The Company is granting stock options to acquire an aggregate of one million common shares in the capital of the Company at an exercise price of $1.40 per common share, expiring on the fifth anniversary of the grant (collectively, the “Stock Option”). The Stock Option vests in stages over the course of two (2) years with 12.5% to vest immediately and a further 12.5% to vest in each three-month period thereafter, and is exercisable quarterly after 12 months, with the balance after 24 months from the Commencement Date. The Stock Options are being granted in accordance with the Company’s stock option plan, and are subject to regulatory approval.
About Valens GroWorks Corp.
Valens GroWorks Corp is a Canadian Securities Exchange listed company with an aggressive acquisition strategy in progress, providing management, consulting, testing and support services to domestic and international licensees, as well as financing the buildout of established, fully-licensed operations pursuant to its investment in Arizona. The Company seeks to capture a broad spectrum of medical marijuana users, as well as recreational users once legalized, in pursuit of its ambitious seed to sale and farm to pharma objectives.
The Company’s wholly-owned subsidiary, Valens Agritech Ltd. (“VAL”), is a post-inspection applicant awaiting the granting of a Controlled Drugs and Substances Dealer’s Licence for the cultivation and processing of marijuana. Based in the Okanagan Valley of British Columbia, VAL anticipates participation in selective clinical trial programs researching the efficacy of medical cannabis.
The Company is about to close the signed Share Exchange Agreement (SEA) with Supra THC Services Inc. (“Supra”) which will become a wholly-owned subsidiary. Supra holds a Health Canada Dealer’s Licence and is providing sector-leading analytical services for Licensed Producers and ACMPR patients.
Connect with Valens GroWorks Corp. (CSE:VGW) to receive an Investor Presentation.
Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the ongoing U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.
“We would like to welcome Dr. Moody as a medical and clinical advisor to our team and we look forward to his contributions in our ongoing FDA Phase 3 clinical study as well as expanding our COVID-19 studies in Canada,” said Michael Frank, CEO of Revive. “Dr. Moody’s experience in clinical epidemiology, data analysis and research are key to our FDA Phase 3 study as we gather clinical data from patients enrolled.”
Numinus and MAPS Public Benefit Corporation announce collaboration agreement to seek approval of MDMA-assisted psychotherapy for PTSD single-arm, open-label trial
First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support patients with posttraumatic stress disorder
Multi-year partnership designates BioSteel as new official sports drink of Philadelphia 76ers team, Training Complex, and the presenting partner of 76ers Training Camp
BioSteel today announced a multi-year deal with the Philadelphia 76ers, making the sports hydration company the official sports drink of the team. BioSteel will also serve as a partner of the Philadelphia 76ers Training Complex, and the presenting partner for 76ers Training Camp, which begins next week.
Achievements with Scalability and Compatibility Pave Way for Next Phase of Advancement
Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) is excited to announce that the Company’s holding, Arcology, a cluster-computing powered AI blockchain ecosystem with unlimited scalability, has updated its working roadmap in response to its Testnet 1.0 results